GW Pharmaceuticals plc : American Depositary Shares Securities Litigation

If you purchased a significant amount of shares of GW Pharmaceuticals Plc American Depositary Shares (NASDAQ: GWPH), you have certain options. Investors should contact us.


Lawsuit Overview

Defendant:GW Pharmaceuticals Plc American Depositary Shares
Date Filed:March 26th, 2021
Sector:Health Care
Industry:Major Pharmaceuticals
Class Start Date:February 3rd, 2021
Class End Date:March 26th, 2021

On February 3, 2021, GW and Jazz Pharmaceuticals Public Limited Company issued a joint press release announcing the Proposed Transaction, pursuant to which GW will merge with Jazz through Jazz’s wholly owned subsidiary Jazz Pharmaceuticals UK Holdings Limited. Under the terms of the Merger Agreement, holders of GW ordinary shares will receive $16.66 2/3 in cash plus an amount of Jazz ordinary shares equal to an exchange ratio that will be calculated based upon Jazz’s share price, and holders of American Depositary Shares of GW will receive approximately $220 in cash and $20 in Jazz stock in consideration for their GW ADSs (the “Merger Consideration”).

On March 15, 2021, GW filed a Schedule 14A Definitive Proxy Statement with the SEC. The Complaint alleges that the Proxy Statement, which recommends that GW stockholders vote in favor of the Proposed Transaction, omits or misrepresents material information concerning, among other things, the Company’s and Jazz’s financial projections and the financial analyses supporting the fairness opinions provided by the Board’s financial advisors.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for GW Pharmaceuticals Plc American Depositary Shares

First Identified Complaint

Catherine Coffman, et al. v. GW Pharmaceuticals plc, et al.

Date Filed:March 26th, 2021
Class Period Start:February 3rd, 2021
Class Period End:March 26th, 2021
First Identified Complaint Filings
#Document TitleFiling Date